Bio Medica Laboratories Ltd. Share Price

Overview

Bio Medica Laboratories Ltd. share price is currently ₹148.24, down by - ₹5.38 (3.5%) from its previous closing price of ₹153.62. The share price has declined -7.51% over the past month and gained 0% over the past year. The stock's 52-week low and high are ₹100.52 and ₹179.34, respectively. Bio Medica Laboratories Ltd. has a market capitalisation of ₹ 210.00 Cr. The share price was last updated on 23 Oct 2026, 03:23 PM IST.

Bio Medica Laboratories Ltd.

BMLL

₹0.00

- ₹5.38

3.50%

Healthcare

₹0.00(%)1D

Updated: 23 Oct 2026, 03:23:12 pm IST

Market Data

Open Price

₹153.31

Prev. Close

₹153.62

₹146.21

Day Low

₹154.32

Day High

₹100.52

52 Week Low

₹179.34

52 Week High

HealthcarePharmaceuticals & Drugs

CategoryMicro Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

13.89

Sector PE

41.82

PB Ratio

9.24

Sector PB

5.48

EPS

10.67

Dividend Yield

0.00

Today's Volume

50.001 K

5 Day Avg. Volume

26.600 K

PEG Ratio

-0.15

Market Cap.

₹ 210.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Corporate Actions will be available shortly.

Mutual Fund Ownership

Mutual Fund Ownership will be available shortly.

About Bio Medica Laboratories Ltd. 👋

Bio Medica Laboratories Limited is an India-based company. The Company is engaged in the manufacturing of pharmaceutical parenteral formulations. It manufactures a variety of products, comprising ethical drugs, generic drugs and over-the-counter drugs (OTC) in the form of injectables, namely liquid injections and dry powder injections. These injectables are available in both single-dose and multi-dose forms, catering to both human and veterinary needs. Its products address a wide range of medical needs and preferences. The Company operates on a Business-to-Business (B2B) model through contract manufacturing and does not deal directly with the end users. It manufactures formulations for various companies according to their specific requirements and specifications for the type of formulation needed. Its product categories include Injectables for the Domestic Market, Injectables for Export, and Injectables for Veterinary Use.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →

Lovelesh Sharma

8 Jul • 1:00 PM · SEBI-Registered Analyst

BEML

TRENDLINE RESISTANCE

BEML

is approaching a major resistance zone on the weekly chart, where a long-term falling trendline continues to cap every rally. * The stock has recovered well from its recent lows, but this overhead supply remains a crucial technical hurdle. * A decisive weekly close above the trendline could mark the beginning of a fresh medium-term uptrend.